Filing Analysis
Nuo Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter of 2026. The filing serves as a formal announcement of the earnings release issued on August 17, 2026.
📋 Key Facts
- Company announced Q2 2026 financial results on August 17, 2026.
- The filing includes a press release as Exhibit 99.
- David E. Jorden (CEO and CFO) signed the report.
Nuo Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on December 16, 2025. The meeting resulted in the successful election of four directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on December 16, 2025.
- Four directors elected: David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer.
- Ratification of MaloneBailey LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Advisory vote on named executive officer compensation was approved with 33,653,458 votes 'For'.
Nuo Therapeutics announced salary increases for its CEO/CFO and CS&O effective October 1, 2025. The company also scheduled its 2025 Annual Meeting of Stockholders for December 16, 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- David E. Jorden (CEO/CFO) salary increased to $325,000 effective Oct 1, 2025.
- Peter A. Clausen (CS&O) salary increased to $290,000 effective Oct 1, 2025.
- The Board cited improvement in business and financial condition in 2025 as the reason for increases.
- Annual Meeting of Stockholders scheduled for December 16, 2025, in Houston, Texas.
Nuo Therapeutics entered into an amendment to its existing Distribution Agreement with Smith+Nephew, Inc. establishing an interim sales agency arrangement. Under this amendment, Smith+Nephew will act as a sales agent for Nuo's Aurix brand products to specific customers in exchange for commissions on net sales.
🚩 Red Flags
- Interim nature of the sales agency arrangement (terminates Dec 31, 2025).
- Potential reliance on a third party's sales force to drive revenue for the core Aurix brand.
📋 Key Facts
- Amendment No. 1 entered into with Smith+Nephew, Inc. on May 14, 2025.
- Establishes an interim sales agency arrangement for the Nuo Aurix brand.
- Smith+Nephew to receive commissions on net sales of products sold to their customers via this agency arrangement.
- The interim arrangement terminates on either December 31, 2025, or upon 30 days' written notice from Smith+Nephew.
- The underlying Distribution Agreement includes a five-year term for supplying private label Aurix brand products with minimum purchase commitments.
Nuo Therapeutics, Inc. completed a private placement of common stock to raise approximately $849,125 in gross proceeds. The offering was conducted at $0.75 per share and included participation from a principal stockholder.
🚩 Red Flags
- Dilutive financing: Issuance of over 1.1 million new shares at a low price point ($0.75).
- Small capital raise: The total proceeds ($849k) are relatively small, suggesting ongoing liquidity needs.
- Related-party transaction: A principal stockholder participated in the private placement.
📋 Key Facts
- Entered into a Securities Purchase Agreement on September 13, 2024.
- Sold 1,132,167 shares of common stock at $0.75 per share.
- Total gross proceeds from the private placement: $849,125.
- Closing date of the transaction: September 19, 2024.
- Charles E. Sheedy, a principal stockholder, participated with an investment of $93,750.
- Proceeds are designated for working capital purposes.
- Post-offering total shares outstanding: 46,598,405.
Nuo Therapeutics announced that Pacific Medical, Inc. exercised a portion of its previously issued warrants on June 27, 2024. This resulted in the issuance of 356,889 shares of common stock through a combination of cash and cashless exercise.
🚩 Red Flags
- Low exercise price of $0.56 per share suggests significant potential dilution for existing shareholders.
📋 Key Facts
- Pacific Medical, Inc. exercised a portion of a warrant originally issued on January 1, 2024.
- Cash exercise: 270,000 shares at $0.56 per share for total proceeds of $151,200.
- Cashless exercise: 86,889 shares issued in exchange for the remaining warrant portion.
- Total new shares issued to Pac Medical: 356,889 shares.
- Post-exercise total outstanding common stock: 45,466,238 shares.
Nuo Therapeutics dismissed its long-term auditor, Marcum LLP, and appointed MaloneBailey, LLP. The dismissal coincides with the company's ongoing struggle to maintain sufficient accounting resources and address material weaknesses in internal controls.
🚩 Red Flags
- Auditor change combined with material weaknesses in internal controls.
- Ongoing 'going concern' uncertainty mentioned in previous audit reports (FY2022 and FY2023).
- Material weakness: Lack of sufficient accounting and financial reporting resources to maintain effective internal controls.
- High risk of delayed filings if the new auditor requires significant remediation of internal controls.
📋 Key Facts
- Effective June 7, 2024, Marcum LLP was dismissed as the independent registered public accounting firm.
- MaloneBailey, LLP (MB) has been engaged as the new auditor for fiscal year ending December 31, 2024.
- Marcum had served as the company's auditor since September 27, 2017.
- The company identified material weaknesses in internal control over financial reporting due to a lack of sufficient accounting and financial reporting resources.
- Previous audit reports for FY2023 and FY2022 contained explanatory paragraphs regarding the company's ability to continue as a going concern.
Nuo Therapeutics, Inc. completed a private placement of 867,833 shares at $0.75 per share to raise approximately $651k for working capital. The offering involved significant participation from company insiders and a principal stockholder.
🚩 Red Flags
- Related-party transactions: Significant investment from insiders including a Board member (Scott M. Pittman), the CS/COO (Peter A. Clausen), and a principal stockholder (Charles E. Sheedy).
- Low share price ($0.75) suggests potential liquidity or valuation concerns common in micro-cap distressed companies.
- Small capital raise ($651k) relative to typical operational needs, suggesting ongoing cash burn issues.
📋 Key Facts
- Date of agreement: May 10, 2024; Closing date: May 20, 2024.
- Total shares sold: 867,833 common stock shares.
- Price per share: $0.75.
- Gross proceeds: $650,875.
- Use of proceeds: Working capital purposes.
- Post-offering total shares outstanding: 45,109,349.
Nuo Therapeutics announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The delay is due to the independent auditor's ongoing review of the company's audited financial statements.
🚩 Red Flags
- Delayed filing of annual report (Form 10-K) often indicates potential issues with internal controls or accounting complexities.
- The delay occurs immediately following a previously filed Form 12b-25 (Notice of Late Filing).
📋 Key Facts
- The Company will not file its Form 10-K by the expected April 16, 2024 deadline.
- The delay is attributed to the need for the independent registered public accounting firm to finalize the review of the FY2023 audited financial statements.
- Management expects to file the Form 10-K no later than April 19, 2024.